Novartis to pay up to US$1b for rights to skin drug
Swiss drugmaker focusing on developing innovative prescription medicines
Geneva
NOVARTIS agreed to buy the rights to a skin-disease drug from developers Galapagos and MorphoSys in a deal that could reach US$1 billion.
Chief executive officer Vas Narasimhan is focusing the Swiss drugmaker on developing innovative prescription medicines.
Novartis will pay 95 million euros (S$151 million) upfront and later payments of up to 850 million euros based on the drug reaching certain regulatory, commercial and sales goals, MorphoSys said in a statement on Thursday.
The payments will be split 50-50 between Mechelen, Belgium-based Galapagos and Planegg, Germany-based MorphoSys.
Mr Narasimhan needs new medicines to counter the impact of cheaper copycats on older products.
The experimental drug known as MOR106 will join a portfolio for skin ailments that includes Cosentyx for psoriasis - on its way to becoming a blockbuster - and Xolair, an asthma drug also prescribed for chronic hives, bolstering Novartis' dermatology business.
Atopic dermatitis, which MOR106 targets, is a common form of eczema that doesn't have many treatments.
MorphoSys raised its 2018 forecasts, with a new sales range that's about triple the old one and a smaller operating loss.
Novartis also agreed to pay royalties to Galapagos and MorphoSys in a range of up to low teens and low 20s as a percentage of sales. BLOOMBERG
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sony deal for Paramount would draw added regulatory scrutiny
Lululemon to shutter Washington distribution center, lay off 128 employees
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom